Contact:

The Quigley Corporation's New Formulation Found to Kill Infectious Herpes Virus

Quigley Pharma's Platform Will Be Used To Develop Formulations Effective Against Other Viruses

DOYLESTOWN, PA, August 7, 2002 - The Quigley Corporation (NASDAQ: QGLY), today announced that the Patent Office of The United States Commerce Department confirmed the assignment to The Quigley Corporation a Patent Application for an all-natural compound which will serve as the platform for what it expects will be a series of formulations effective in killing various virus strains. This new platform has been used to develop a formulation that has been found in two in vitro studies to be effective in killing the infectious Herpes Virus (HSV1).

The Quigley-sponsored studies are being conducted under the direction of world-renowned virologist Professor John Oxford, and will be broadened to determine the compound's effectiveness against other pathogens.

John Oxford is Professor of Virology at St. Bartholomew's and The Royal London School of Medicine and Dentistry at the University of London. He is the co-author of two standard texts on Influenza and Virology and has published 250 scientific papers throughout the world. Professor Oxford serves as the Scientific Director of Retroscreen, Ltd., the College's research virology company.

Professor Oxford stated, "The new Quigley Pharma platform is innovative and has clear advantages over existing herpes therapies. There is additional serious potential against a range of other important human viruses."

Guy J. Quigley, President, Chairman and Chief Executive Officer of The Quigley Corporation, stated: "Over the last two years, our research and development efforts at Quigley Pharma, under the direction of Dr. Richard Rosenbloom, have created a pipeline of potential new medications to bring to the market."

Dr. Rosenbloom stated: "This all-natural formulation will initially be developed as a topical application and preparations are being made to proceed to the next level of clinical development."

The results of the in vitro Retroscreen studies will be submitted for publication in a recognized scientific journal by Professor John Oxford, Dr Rob Lambkin and Dr Ramani Eswarasaran.

The Quigley Corporation (NASDAQ: QGLY) is a leading developer and marketer of diversified health products including the Cold-Eeze® family of patented zinc gluconate glycine (ZIGG™) lozenges, gums and sugar free tablets. Cold-Eeze is the only (ZIGG™) lozenge proven in two double-blind studies to reduce the duration of the common cold from 7.6 to 4.4 days or by 42%. In addition to Over-The-Counter (OTC) products, the Company has formed Quigley Pharma Inc. (www.QuigleyPharma.com), a wholly owned ethical pharmaceutical subsidiary, to introduce a line of patented prescription drugs. The Quigley Corporation's customers include leading national wholesalers and distributors, as well as independent and chain food, drug and mass merchandise stores and pharmacies.

Certain statements in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and involve known and unknown risk, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from the results, performance or achievements expressed or implied by the forward-looking statement. Factors that impact such forward-looking statements include, among others, changes in worldwide general economic conditions, changes in interest rates, government regulations, and worldwide competition.